Arch Therapeutics (OTCMKTS:ARTH) was downgraded by analysts at Ifs Securities from a “strong-buy” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday.
Several other equities research analysts also recently commented on ARTH. ValuEngine downgraded shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. Zacks Investment Research raised shares of Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Friday, December 1st. Finally, HC Wainwright set a $3.00 price objective on shares of Arch Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Arch Therapeutics has an average rating of “Hold” and a consensus price target of $2.17.
Shares of Arch Therapeutics (OTCMKTS:ARTH) opened at $0.31 on Wednesday. The company has a market cap of $49.68, a PE ratio of -7.65 and a beta of 0.52. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89.
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.